FDA staffers question safety of Sparlon for ADHD

FDA staffers have raised questions about potentially serious health risks posed by Cephalon's Sparlon for ADHD. One staffer noted last year that the risks were too serious to permit approval and another raised questions about skin rashes associated with the therapy. Sparlon is currently sold as Provigil, a sleep drug. An FDA advisory panel meets on Sparlon tomorrow.

- read the report from the Kindred Times